特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
363133

カテプシンL:パイプライン製品の分析

Cathepsin L (EC 3.4.22.15) - Pipeline Review, H1 2016

出版日: | 発行: Global Markets Direct | ページ情報: 英文 30 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
カテプシンL:パイプライン製品の分析
出版日: 2016年06月15日
発行: Global Markets Direct
ページ情報: 英文 30 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、カテプシンL薬剤の開発状況関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

カテプシンLの概要

治療薬の開発

カテプシンL:開発中の製品 - 開発段階別

カテプシンL:開発中の製品 - 治療範囲別

カテプシンL:開発中の製品 - 適応症別

カテプシンL:パイプライン製品の概況

  • 初期段階の製品

カテプシンL:企業で開発中の製品

カテプシンL:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

カテプシンLの治療薬開発に従事している企業

  • OXiGENE, Inc.
  • Phelix Therapeutics, LLC
  • Virobay Inc.

カテプシンL:薬剤プロファイル

カテプシンL:休止中のプロジェクト

カテプシンL:主なニュースとプレスリリース

付録

目次
Product Code: GMDHC0113TDB

Summary:

Global Markets Direct's, 'Cathepsin L (EC 3.4.22.15) - Pipeline Review, H1 2016', provides in depth analysis on Cathepsin L (EC 3.4.22.15) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin L (EC 3.4.22.15), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin L (EC 3.4.22.15) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cathepsin L (EC 3.4.22.15)
  • The report reviews Cathepsin L (EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cathepsin L (EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cathepsin L (EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cathepsin L (EC 3.4.22.15) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cathepsin L (EC 3.4.22.15)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cathepsin L (EC 3.4.22.15) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cathepsin L (EC 3.4.22.15) Overview
  • Therapeutics Development
    • Cathepsin L (EC 3.4.22.15) - Products under Development by Stage of Development
    • Cathepsin L (EC 3.4.22.15) - Products under Development by Therapy Area
    • Cathepsin L (EC 3.4.22.15) - Products under Development by Indication
  • Cathepsin L (EC 3.4.22.15) - Pipeline Products Glance
    • Early Stage Products
  • Cathepsin L (EC 3.4.22.15) - Products under Development by Companies
  • Cathepsin L (EC 3.4.22.15) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cathepsin L (EC 3.4.22.15) - Companies Involved in Therapeutics Development
    • OXiGENE, Inc.
    • Phelix Therapeutics, LLC
    • Virobay Inc.
  • Cathepsin L (EC 3.4.22.15) - Drug Profiles
    • Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KGP-94 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-285 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-825 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cathepsin L (EC 3.4.22.15) - Dormant Projects
  • Cathepsin L (EC 3.4.22.15) - Featured News & Press Releases
    • Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference
    • Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference
    • Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by OXiGENE, Inc., H1 2016
  • Pipeline by Phelix Therapeutics, LLC, H1 2016
  • Pipeline by Virobay Inc., H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.